Eli Lilly cuts exports of ‘non-essential’ drugs to Russia

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Indianapolis-based Eli Lilly and Co. said Tuesday that it has stopped exporting “non-essential” medications to Russia in response to the country’s invasion of Ukraine.

Additionally, the pharmaceutical giant said in a statement that it had “suspended all investments, promotional activities, and new clinical trials in Russia.”

Lilly said it would continue providing life-saving drugs to Russia. The company is one of the world’s largest sellers of insulin for diabetes and markets several cancer medications, including Alimta, Erbitux and Cyramza.

“Our Russian operations are now only focused on ensuring people suffering from diseases like cancer and diabetes continue to get the Lilly medicines they need,” the company said. “Should we generate any profits from our sales in Russia, we will donate them to organizations dedicated to humanitarian relief.”

Lilly joins several other drug companies that have reduced operations in Russia to various degrees, including Novartis, AbbVie, Johnson & Johnson, Bayer, Abbott Laboratories and Pfizer.

“For nearly 150 years, Lilly has worked to ensure patients have access to the medicines they need, no matter where they may live,” the company said. “We have an ethical and moral obligation to help alleviate human suffering and to protect the lives of patients.”

On March 3, Lilly announced it was donating $7.5 million worth of insulin and $1.8 million worth of the COVID-19 treatment baricitinib to two different U.S. not-for-profits doing humanitarian relief work in Ukraine.

In addition, it said Lilly’s corporate foundation was donating $500,000 to each of two humanitarian agencies doing work in the region, and matching employee donations up to an additional $500,000.

Russia and Ukraine represent a small fraction of Lilly’s business. Revenue from the countries combined accounted for less than 1% of sales last year, the company said. Lilly’s 2021 revenue was $28.3 billion.

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

9 thoughts on “Eli Lilly cuts exports of ‘non-essential’ drugs to Russia

    1. JL – here’s a good definition, and all that they, as an American-based company, need to provide for Russia: “Our Russian operations are now only focused on ensuring people suffering from diseases like cancer and diabetes continue to get the Lilly medicines they need.” Frankly, they are lucky that we are taking care of the common person in Russian and not punishing them for their government’s brutality in Ukraine. That’s because we’re civilized people. Um… and did you notice the part about this is a decision made by a company, not the government. You must see government intervention everywhere you turn.

  1. Does anyone else find it ironic that Lilly will continue to provide life-saving drugs to Russia, while the world watches that country bomb and kill the Ukrainian citizens every day?

    1. Wow, you’re in favor of hurting Russian citizens because you don’t like that the Russian government is doing?

    2. As a cancer survivor myself, I agree with this tough call by Lilly. It was pure luck that I was born where access to medical care is available.

    1. DL, re-read: “Our Russian operations are now only focused on ensuring people suffering from diseases like cancer and diabetes continue to get the Lilly medicines they need.” I do not know what medicines this leaves out, but it seems they are taking care of people with the most serious of illnesses.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In